<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02132624</url>
  </required_header>
  <id_info>
    <org_study_id>003:TCELL</org_study_id>
    <secondary_id>2013-001393-19</secondary_id>
    <nct_id>NCT02132624</nct_id>
  </id_info>
  <brief_title>CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.</brief_title>
  <official_title>CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AFA Försäkring AB, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and
      efficacy in patients with B cell lymphoma or leukemia. The CAR consists of a CD19 targeting
      antibody scFv with three intracellular signaling domains derived from CD3 zeta, CD28 and
      4-1BB. Autologous T cells will be gene engineered with the CAR gene using a retrovirus
      vector. Prior to T cell infusion, the patients will be subjected to preconditioning
      treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse
      reactions, persistence of CAR T cells and efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAR T cell persistence</measure>
    <time_frame>At week 1 and 5, there after every 3 months post treatment up to 24 months</time_frame>
    <description>Presence of circulating CAR T cells will be evaluated with flow cytometry and real time PCR in patient blood.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor load</measure>
    <time_frame>Every 3 months post treatment up to 24 months</time_frame>
    <description>Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>B cell number and immunoglobulins</measure>
    <time_frame>Weekly for 5 weeks, then every 3 months post treatment up to 24 months</time_frame>
    <description>Number of blood B cells and immunoglobulins will be evaluated by routine diagnostics</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>B Cell Lymphoma</condition>
  <condition>B Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous 3rd generation CD19-targeting CAR T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous 3rd generation CD19-targeting CAR T cells</intervention_name>
    <description>Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.</description>
    <arm_group_label>CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory CD19+ B-cell lymphoma or leukemia.

          -  Measurable disease.

          -  Performance status ECOG 0-2.

          -  &gt;18 years old.

          -  Fertile females/males must consent to use contraceptives during participation of the
             trial.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Any significant medical or psychiatric illness that would prevent the patient from
             giving informed consent or from following the study procedures.

          -  Patients with primary CNS lymphoma.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic
             infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV)
             infection).

          -  Other serious underlying medical conditions, which, in the Investigator's judgment,
             could impair the ability of the patient.

          -  Treatment with an investigational product within 30 days prior to enrollment, or at
             least 5 half lives of that drug, which is longest.

          -  Patients that do not consent to that tissue and blood samples are stored in a biobank.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelica Loskog, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunilla Enblad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Hagberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University Hospital, Dept of Oncology</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2014</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

